TACE plus immunotherapy for high-risk liver cancer before surgery
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests whether a combination of two therapies—targeted chemotherapy delivered directly to the liver (TACE) plus immunotherapy (atezolizumab) and a targeted drug (bevacizumab)—can keep liver cancer from coming back after surgery. It is for people whose tumors can be surgically removed but are at high risk of recurrence.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 75 years old.
- Your liver cancer (HCC) must be confirmed by a biopsy or pathology report.
- Your cancer must be able to be surgically removed, and you are considered at high risk for it coming back (for example, the main tumor is larger than 5 cm, or you have more than 3 tumors, or the cancer has spread into small or medium blood vessels).
- You must not have had any prior treatments for your liver cancer (like surgery, chemotherapy, or other local therapies).
- You must not have a history of organ transplant, uncontrolled fluid buildup in your belly or lungs, or serious bleeding from enlarged veins in your esophagus in the last 6 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests combining TACE (a procedure to block the tumor's blood supply) with immunotherapy drugs for liver cancer that has not spread outside the liver. It is for people who have not had any prior treatment for their liver cancer and are healthy enough for TACE.
This trial tests whether adding two drugs (atezolizumab and bevacizumab) before and after surgery can lower the chance of liver cancer coming back in people with high-risk HCC. You must be eligible for surgical removal of your tumor.
This trial tests a combination of treatments for liver cancer that cannot be removed with surgery. It uses a procedure to block the tumor's blood supply plus two drugs that help the immune system fight the cancer. This may help shrink tumors and slow the disease.
This trial tests whether a liver-directed treatment called TACE (transarterial chemoembolization) after surgery can help prevent liver cancer from coming back in people with high-risk features.
This study combines a liver-directed procedure called TACE (which blocks blood flow to the tumor and delivers chemotherapy directly to it) with two immunotherapy drugs and a targeted therapy (bevacizumab). The goal is to see if this combination can shrink liver cancer that cannot be surgically removed, without the cancer having spread elsewhere.
This trial tests if giving a combination of drugs (apatinib and camrelizumab) along with a procedure called TACE before surgery can help treat a certain type of liver cancer. The goal is to shrink the tumor before the operation to improve outcomes.
Hear when a new Resectable Hepatocellular Carcinoma With High Risk of Recurrence trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.